Investor Relations :: Ocuphire Pharma, Inc. (OCUP)
Investor S Rexahn. The Investor Relations website contains information about Rexahn Pharmaceuticals, Inc.'s business for stockholders, potential...
Read Investors.rexahn.com news digest here: view the latest Investor S Rexahn articles and content updates right away or get to their most visited pages. Investors.rexahn.com is not yet rated by Alexa and its traffic estimate is unavailable. It seems that Investor S Rexahn content is notably popular in USA. We haven’t detected security issues or inappropriate content on Investors.rexahn.com and thus you can safely use it. Investors.rexahn.com is hosted with Confluence Networks Inc (Virgin Islands, British) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
N/A
Visitors daily -
N/A
Pageviews daily -
N/A
Google PR -
N/A
Alexa rank
Best pages on Investors.rexahn.com
-
Annual Reports and Proxies | Rexahn Pharmaceuticals, Inc.
The Investor Relations website contains information about Rexahn Pharmaceuticals, Inc. business for stockholders, potential investors, and financial analysts.
-
Investor Relations :: Rexahn Pharmaceuticals, Inc. (REXN)
Email Alerts Stock Information {tplLang.change| toLang tLang} {data.pricedata.change | asQHLast tLang } ({data.pricedata.changepercent ...
-
©2016 by Rexahn Pharmaceuticals, Inc. All rights reserved Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850
Investors.rexahn.com news digest
-
3 years
Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical ...
Durability of Nyxol’s Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD
Ocuphire Invited to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase on January 28, 2021... -
3 years
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyx...
Nyxol has Potential to be a New Treatment Option for Reversal of Pharmacologically-Induced Pupil Dilation
Top-Line Data for MIRA-2 Expected by End of Q1 2021
FARMINGTON HILLS, Mich., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced... -
3 years
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Visi...
Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication
Top Line Data from LYNX-1 Expected 3Q2021
FARMINGTON HILLS, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced... -
3 years
Ocuphire to Present at the LifeSci Partners 10th Annual Healthcare Corporate Acc...
FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that...
Domain history
| Web host: | Confluence Networks Inc |
| Registrar: | Network Solutions, LLC |
| Registrant: | PERFECT PRIVACY, LLC |
| Updated: | March 04, 2024 |
| Expires: | January 18, 2026 |
| Created: | January 18, 2001 |
Whois record
Safety scores
Trustworthiness
GoodChild safety
N/A
